Greenwich LifeSciences, Inc.

NASDAQ: GLSI · Healthcare · Biotechnology

PublicHQ Stafford, TX · Fort BendCIK 0001799788Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 32DQ —GM —SS 43

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ return on equity, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$19.4M

Employees

as of 2026-08-12

Market cap

$228.2M

as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$19.4M-$19.4M2025

Operating income-$19.4M-$19.4M2025

Total assets$6.2M$6.2M2025

Liabilities$5.8M$5.8M2025

Equity$353.2k$353.2k2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Greenwich LifeSciences, Inc.’s financial profile?

Greenwich LifeSciences, Inc. earned -$19.4M in FY2025 net income.

Peers · Healthcare

Turn Therapeutics Inc.——Alamar Biosciences, Inc.——Aurora Cannabis Inc.——Immunic, Inc.——AN2 Therapeutics, Inc.——Galectin Therapeutics Inc.——

Neighbors

Fort Bend →

Applied Optoelectronics, Inc.$455.7M66B CVR Energy, Inc.$7.2B60C CVR Partners, LP$606.0M69B Microvast Holdings, Inc.$427.5M45D Vanjia Corporation$82.7k29D Team, Inc.$896.5M52D

Key facts

CEOSnehal S. Patel

SectorHealthcare

IndustryBiotechnology

HeadquartersStafford, TX

ExchangeNASDAQ: GLSI

Employees13

IPO date2020-09-25

Latest filings

10-Q2026-08-11 10-Q2026-06-04 10-K2026-06-01 8-K2025-12-18 10-Q2025-11-14 DEF 14A2025-11-03 10-Q2025-08-14 8-K2025-07-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.